At a glance
ClinicalIndex Comparison Record- ✓Biopsy-proven relapsed or refractory CD20 positive, grade 1-3a follicular lymphoma (biopsy within 3 months)
- ✓Age 18 years or over
- ✓Prior therapy with at least one line of immunochemotherapy (rituximab monotherapy permitted if also received immunochemotherapy)
- ✓Assessable disease by PET-CT with at least one involved node >1.5cm or extranodal lesion >1cm
- ✕Current or within 1 year transformation to high-grade lymphoma or grade 3b follicular lymphoma (historical transformation >1 year ago permitted)
- ✕Non-FDG avid disease
- ✕Prior allogenic stem cell transplantation or solid organ transplant
- ✕Prior treatment with lenalidomide
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
In the news
1 article- Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) PatientsGlobeNewswire Biotech·2026-06-11press release
Matched to this trial by ClinicalIndexfrom reputable biotech & medical press.
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy (REFRACT): A Randomised Phase II Trial of Investigator Choice Standard Therapy Versus Sequential Novel Therapy Experimental Arms
In Brief
A Phase 2 clinical trial evaluating Epcoritamab, Lenalidomide, and 9 other interventions for Relapsed Follicular Lymphoma and Refractory Follicular Lymphoma. Currently recruiting, targeting 284 participants across 25 sites.
Detailed Summary
The aim of the REFRACT clinical trial is to find new therapies with improved outcomes compared to the current standard treatment available, in patients with relapsed or refractory follicular lymphoma. This will be done by comparing patients who have received a new treatment against patients who receive standard treatment based on their response to the treatment received.
Study Details
Timeline
Interventions
Bispecific antibody
Immunomodulatory agent
Monoclonal antibody
Monoclonal antibody
Alkylating agent (chemotherapy drug)
Antineoplastic, Vinca Alkaloid
Anthracycline
Alkylating agent (chemotherapy drug)
Corticosteroid
The drug used in round 2 is yet to be confirmed, round 2 is estimated to open in Q4 2025 and the record will be updated when the drug has been confirmed
The drug used in round 3 is yet to be confirmed, round 3 is estimated to open in Q3 2027 and the record will be updated when the drug has been confirmed